{
    "2018-05-21": [
        [
            {
                "time": "2018-05-17",
                "original_text": "Migraine Space in Focus as AMGN/NVS' Aimovig Gets FDA Nod",
                "features": {
                    "keywords": [
                        "Migraine",
                        "Aimovig",
                        "FDA",
                        "Nod"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-30",
                "original_text": "Eli Lilly’s Neuroscience Products in Q1 2018",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Neuroscience",
                        "Q1 2018"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-30",
                "original_text": "Eli Lilly’s Human Pharmaceuticals Business in Q1 2018",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Human Pharmaceuticals",
                        "Q1 2018"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-17",
                "original_text": "Bristol-Myers Squibb and Three Additional Stocks Under Scanner in the Drug Makers Space",
                "features": {
                    "keywords": [
                        "Bristol-Myers Squibb",
                        "Drug Makers"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}